Evidence map›Paper›PMID 42170271›Full record

ArticleTranslational lung cancer research2026

Survival, toxicity, and sequencing: navigating the new first-line standard established by FLAURA2.

Satoshi Ikeda, Keigo Araki, Mai Kitagawa, Natsuno Makihara, Yutaro Nagata, Kazuki Fujii, Kiyori Yoshida, Tatsuki Ikoma, Kahori Nakahama, Yuki Takeyasu and 3 more

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Satoshi IkedaDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.ORCID https://orcid.org/0000-0001-5203-7911
Keigo ArakiDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Mai KitagawaDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Natsuno MakiharaDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Yutaro NagataDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Kazuki FujiiDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Kiyori YoshidaDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Tatsuki IkomaDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Kahori NakahamaDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Yuki TakeyasuDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Utae KatsushimaDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Yuta YamanakaDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Takayasu KurataDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

epidermal growth factor receptor (EGFR)Non-small cell lung cancer (NSCLC)osimertinib

Identifiers

PMID42170271
PMCPMC13186675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.